These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9651905)

  • 1. Postmenopausal hormone replacement therapy and autoantibodies against oxidized LDL.
    Heikkinen AM; Niskanen L; Ylä-Herttuala S; Luoma J; Tuppurainen MT; Komulainen M; Saarikoski S
    Maturitas; 1998 Jun; 29(2):155-61. PubMed ID: 9651905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term vitamin D3 supplementation may have adverse effects on serum lipids during postmenopausal hormone replacement therapy.
    Heikkinen AM; Tuppurainen MT; Niskanen L; Komulainen M; Penttilä I; Saarikoski S
    Eur J Endocrinol; 1997 Nov; 137(5):495-502. PubMed ID: 9405029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the response of serum lipids and lipoproteins to postmenopausal hormone replacement therapy modified by ApoE genotype?
    Heikkinen AM; Niskanen L; Ryynänen M; Komulainen MH; Tuppurainen MT; Parviainen M; Saarikoski S
    Arterioscler Thromb Vasc Biol; 1999 Feb; 19(2):402-7. PubMed ID: 9974425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relation of oxidized LDL autoantibodies and long-term hormone replacement therapy to ultrasonographically assessed atherosclerotic plaque quantity and severity in postmenopausal women.
    Koivu TA; Dastidar P; Jokela H; Nikkari ST; Jaakkola O; Koivula T; Punnonen R; Lehtimäki T
    Atherosclerosis; 2001 Aug; 157(2):471-9. PubMed ID: 11472749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation of myeloperoxidase promoter polymorphism and long-term hormone replacement therapy to oxidized low-density lipoprotein autoantibodies in postmenopausal women.
    Mäkelä R; Dastidar P; Jokela H; Jaakkola O; Saarela M; Punnonen R; Lehtimäki T
    Scand J Clin Lab Invest; 2006; 66(5):371-83. PubMed ID: 16901848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of postmenopausal hormone replacement therapy with and without vitamin D3 on circulating levels of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D.
    Heikkinen A; Parviainen MT; Tuppurainen MT; Niskanen L; Komulainen MH; Saarikoski S
    Calcif Tissue Int; 1998 Jan; 62(1):26-30. PubMed ID: 9405729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study.
    Heikkinen AM; Parviainen M; Niskanen L; Komulainen M; Tuppurainen MT; Kröger H; Saarikoski S
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2476-82. PubMed ID: 9253321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of hormone-replacement therapy on endogenous nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate.
    Imthurn B; Rosselli M; Jaeger AW; Keller PJ; Dubey RK
    J Clin Endocrinol Metab; 1997 Feb; 82(2):388-94. PubMed ID: 9024224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does vitamin D3 have negative effects on serum levels of lipids? A follow-up study with a sequential combination of estradiol valerate and cyproterone acetate and/or vitamin D3.
    Tuppurainen M; Heikkinen AM; Penttilä I; Saarikoski S
    Maturitas; 1995 Jun; 22(1):55-61. PubMed ID: 7666817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of hormone replacement therapy on total serum anti-oxidant potential and oxidized LDL/β2-glycoprotein I complexes in postmenopausal women.
    Darabi M; Ani M; Movahedian A; Zarean E; Panjehpour M; Rabbani M
    Endocr J; 2010; 57(12):1029-34. PubMed ID: 20978364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation of aromatase gene polymorphism and hormone replacement therapy to serum estradiol levels, bone mineral density, and fracture risk in early postmenopausal women.
    Salmen T; Heikkinen AM; Mahonen A; Kröger H; Komulainen M; Pallonen H; Saarikoski S; Honkanen R; Mäenpää PH
    Ann Med; 2003; 35(4):282-8. PubMed ID: 12846271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a HMG-CoA reductase inhibitor combined with hormone replacement therapy on lipid metabolism in Japanese women with hypoestrogenic lipidemia: a multicenter double-blind controlled prospective study.
    Ohta H; Komukai S; Sugimoto I; Fuyuki T; Makita K; Takamatsu K; Horiguchi F; Nozawa S
    Maturitas; 1998 Jun; 29(2):163-71. PubMed ID: 9651906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of hormone replacement therapy on oxidized low density lipoprotein levels and paraoxonase activity in postmenopausal women.
    Topçuoglu A; Uzun H; Aydin S; Kahraman N; Vehid S; Zeybek G; Topçuoglu D
    Tohoku J Exp Med; 2005 Jan; 205(1):79-86. PubMed ID: 15635276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen replacement decreases the level of antibodies against oxidized low-density lipoprotein in postmenopausal women with coronary heart disease.
    Hoogerbrugge N; Zillikens MC; Jansen H; Meeter K; Deckers JW; Birkenhäger JC
    Metabolism; 1998 Jun; 47(6):675-80. PubMed ID: 9627365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of long-term hormone replacement therapy on in vivo and in vitro markers of lipid oxidation.
    Rontu R; Solakivi T; Teisala K; Lehtimäki T; Punnonen R; Jokela H
    Free Radic Res; 2004 Feb; 38(2):129-37. PubMed ID: 15104206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: a population-based 5-year randomized trial.
    Komulainen M; Kröger H; Tuppurainen MT; Heikkinen AM; Alhava E; Honkanen R; Jurvelin J; Saarikoski S
    J Clin Endocrinol Metab; 1999 Feb; 84(2):546-52. PubMed ID: 10022414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation of androgen receptor gene polymorphism to bone mineral density and fracture risk in early postmenopausal women during a 5-year randomized hormone replacement therapy trial.
    Salmén T; Heikkinen AM; Mahonen A; Kröger H; Komulainen M; Pallonen H; Saarikoski S; Honkanen R; Mäenpää PH
    J Bone Miner Res; 2003 Feb; 18(2):319-24. PubMed ID: 12568409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No antioxidant effect of combined HRT on LDL oxidizability and oxidative stress biomarkers in treated post-menopausal women.
    Bureau I; Laporte F; Favier M; Faure H; Fields M; Favier AE; Roussel AM
    J Am Coll Nutr; 2002 Aug; 21(4):333-8. PubMed ID: 12166530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of hormone replacement therapy on the oxidation of low density lipoprotein in postmenopausal women.
    Mc Manus J; Mc Eneny J; Thompson W; Young IS
    Atherosclerosis; 1997 Nov; 135(1):73-81. PubMed ID: 9395275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of endurance exercise and hormone replacement therapy on serum lipids in older women.
    Binder EF; Birge SJ; Kohrt WM
    J Am Geriatr Soc; 1996 Mar; 44(3):231-6. PubMed ID: 8600189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.